Basilea and Innoviva partner to sell antibiotic Zevtera in the U.S. for infections like MRSA.
Basilea Pharmaceutica and Innoviva Specialty Therapeutics have agreed to commercialize the antibiotic Zevtera (ceftobiprole) in the U.S., targeting infections like MRSA. Basilea will receive a $4 million upfront payment plus royalties. Innoviva will handle marketing and distribution, aiming to address the need for effective antibiotic treatments for serious infections.
3 months ago
7 Articles